New Insulins: Opportunities in the Treatment of Type 1 Diabetes
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v13i1.265 |
Resumo: | Type 1 diabetes (T1D) is one of the focuses of scientific research worldwide. Particularities such as its incidence in the younger population, its multifactorial character and the possibility of giving these patients a quality of life and an average life expectancy equal to that of a healthy individual have led to a great investment in research in this area. Since the therapeutic approach of this disease is based on the use of insulin, the progress in the development of new molecules is remarkable. Currently available are new insulins of ultra-fast and ultra-prolonged action, which have revolutionized the treatment of T1D, namely by allowing the mimicking of physiological insulin secretion and thus increasing the effectiveness and safety of therapy. These new insulins have administration and action profiles more adapted and flexible to the diabetic’s day-to-day life, which allows for the optimization of the therapeutic outcome. |
id |
RCAP_baa0aceb304bad1c8101416d24fd8aee |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/316 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
New Insulins: Opportunities in the Treatment of Type 1 DiabetesAs Novas Insulinas: Oportunidades no Tratamento da Diabetes Tipo 1Type 1 diabetes (T1D) is one of the focuses of scientific research worldwide. Particularities such as its incidence in the younger population, its multifactorial character and the possibility of giving these patients a quality of life and an average life expectancy equal to that of a healthy individual have led to a great investment in research in this area. Since the therapeutic approach of this disease is based on the use of insulin, the progress in the development of new molecules is remarkable. Currently available are new insulins of ultra-fast and ultra-prolonged action, which have revolutionized the treatment of T1D, namely by allowing the mimicking of physiological insulin secretion and thus increasing the effectiveness and safety of therapy. These new insulins have administration and action profiles more adapted and flexible to the diabetic’s day-to-day life, which allows for the optimization of the therapeutic outcome.A diabetes tipo 1 (DT1) é um dos focos da investigação científica mundial. Particularidades como a sua incidência na população mais jovem, o seu carácter multifatorial e a possibilidade de dar a estes doentes uma qualidade de vida e uma esperança média de vida igual a um indivíduo saudável fazem com que exista um grande investimento na investigação nesta área. Sendo a abordagem terapêutica desta doença baseada na utilização de insulina, são notáveis os progressos no desenvolvimento de novas moléculas. Atualmente, encontram-se disponíveis novas insulinas de ação ultrarrápida e ultra prolongada, que vieram revolucionar o tratamento da DT1, nomeadamente por permitirem mimetizar a secreção fisiológica de insulina e, deste modo, aumentar a efetividade e segurança da terapêutica. Estas novas insulinas apresentam perfis de administração e de ação mais adaptados e flexíveis ao dia-a-dia do diabético, o que permite otimizar o resultado da terapêutica.Formifarma2021-07-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v13i1.265https://doi.org/10.25756/rpf.v13i1.265Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 13 No 1 (2021): Janeiro/Fevereiro/Março; 8-18Revista Portuguesa de Farmacoterapia; v. 13 n. 1 (2021): Janeiro/Fevereiro/Março; 8-182183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/316http://revista.farmacoterapia.pt/index.php/rpf/article/view/316/288Direitos de Autor (c) 2021 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessCabral, Ana Cristina GasparSemedo, MariaLavrador, Mariana AveiroLavrador, MartaCastel-Branco, MargaridaFigueiredo, Isabel Vitória2023-09-01T04:35:08Zoai:ojs.farmacoterapia.pt:article/316Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:42.373433Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes As Novas Insulinas: Oportunidades no Tratamento da Diabetes Tipo 1 |
title |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
spellingShingle |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes Cabral, Ana Cristina Gaspar |
title_short |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
title_full |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
title_fullStr |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
title_full_unstemmed |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
title_sort |
New Insulins: Opportunities in the Treatment of Type 1 Diabetes |
author |
Cabral, Ana Cristina Gaspar |
author_facet |
Cabral, Ana Cristina Gaspar Semedo, Maria Lavrador, Mariana Aveiro Lavrador, Marta Castel-Branco, Margarida Figueiredo, Isabel Vitória |
author_role |
author |
author2 |
Semedo, Maria Lavrador, Mariana Aveiro Lavrador, Marta Castel-Branco, Margarida Figueiredo, Isabel Vitória |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Cabral, Ana Cristina Gaspar Semedo, Maria Lavrador, Mariana Aveiro Lavrador, Marta Castel-Branco, Margarida Figueiredo, Isabel Vitória |
description |
Type 1 diabetes (T1D) is one of the focuses of scientific research worldwide. Particularities such as its incidence in the younger population, its multifactorial character and the possibility of giving these patients a quality of life and an average life expectancy equal to that of a healthy individual have led to a great investment in research in this area. Since the therapeutic approach of this disease is based on the use of insulin, the progress in the development of new molecules is remarkable. Currently available are new insulins of ultra-fast and ultra-prolonged action, which have revolutionized the treatment of T1D, namely by allowing the mimicking of physiological insulin secretion and thus increasing the effectiveness and safety of therapy. These new insulins have administration and action profiles more adapted and flexible to the diabetic’s day-to-day life, which allows for the optimization of the therapeutic outcome. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-23 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v13i1.265 https://doi.org/10.25756/rpf.v13i1.265 |
url |
https://doi.org/10.25756/rpf.v13i1.265 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/316 http://revista.farmacoterapia.pt/index.php/rpf/article/view/316/288 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2021 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2021 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 13 No 1 (2021): Janeiro/Fevereiro/Março; 8-18 Revista Portuguesa de Farmacoterapia; v. 13 n. 1 (2021): Janeiro/Fevereiro/Março; 8-18 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129987109879808 |